Bio-Rad Laboratories (FRA:BUWA) Cyclically Adjusted FCF per Share: €9.10 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:BUWA Bio-Rad Laboratories Inc FRA:BUWA
71 GF Score
Price €266.00
GF Value €277.82
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Bio-Rad Laboratories Cyclically Adjusted FCF per Share?

Bio-Rad Laboratories FRA:BUWA +1.45% 71 Cyclically Adjusted FCF per Share is €9.10 as of Mar. 2026. GuruFocus rates FRA:BUWA with a GF Score™ of 71/100 and a GF Value™ of €277.82 (Fairly Valued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Bio-Rad Laboratories's adjusted free cash flow per share for the three months ended in Mar. 2026 was €2.506. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €9.10 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Bio-Rad Laboratories's average Cyclically Adjusted FCF Growth Rate was 16.00% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 10.40% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 10.30% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 9.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Bio-Rad Laboratories was 93.80% per year. The lowest was -3.50% per year. And the median was 10.50% per year.

As of today (2026-07-18), Bio-Rad Laboratories's current stock price is €266.00. Bio-Rad Laboratories's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €9.10. Bio-Rad Laboratories's Cyclically Adjusted Price-to-FCF of today is 29.23.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Bio-Rad Laboratories was 129.56. The lowest was 23.35. And the median was 56.50.


Bio-Rad Laboratories  (FRA:BUWA) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Bio-Rad Laboratories's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=266.00/9.10
=29.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Bio-Rad Laboratories was 129.56. The lowest was 23.35. And the median was 56.50.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Bio-Rad Laboratories Cyclically Adjusted FCF per Share Related Terms


Bio-Rad Laboratories Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Bio-Rad Laboratories's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Rad Laboratories Cyclically Adjusted FCF per Share Chart

Bio-Rad Laboratories Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.36 6.97 7.32 8.30 8.41

Bio-Rad Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.35 8.15 7.80 8.41 9.10

FRA:BUWA vs GKOS, BRKR, PODD: Cyclically Adjusted FCF per Share Comparison

For the Medical Devices subindustry, Bio-Rad Laboratories's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bio-Rad Laboratories Cyclically Adjusted Price-to-FCF vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bio-Rad Laboratories's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Bio-Rad Laboratories's Cyclically Adjusted Price-to-FCF falls into.


FRA:BUWA
71GF Score
Bio-Rad Laboratories Inc FRA:BUWA
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bio-Rad Laboratories Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Bio-Rad Laboratories's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=2.506/330.2130*330.2130
=2.506

Current CPI (Mar. 2026) = 330.2130.

Bio-Rad Laboratories Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 1.371 241.018 1.878
201609 0.365 241.428 0.499
201612 1.575 241.432 2.154
201703 -2.986 243.801 -4.044
201706 0.978 244.955 1.318
201709 0.231 246.819 0.309
201712 1.213 246.524 1.625
201803 0.354 249.554 0.468
201806 1.449 251.989 1.899
201809 1.138 252.439 1.489
201812 1.488 251.233 1.956
201903 0.568 254.202 0.738
201906 3.909 256.143 5.039
201909 2.090 256.759 2.688
201912 4.107 256.974 5.278
202003 1.232 258.115 1.576
202006 2.186 257.797 2.800
202009 3.260 260.280 4.136
202012 6.678 260.474 8.466
202103 2.618 264.877 3.264
202106 3.613 271.696 4.391
202109 5.505 274.310 6.627
202112 3.354 278.802 3.972
202203 0.528 287.504 0.606
202206 1.141 296.311 1.272
202209 -0.562 296.808 -0.625
202212 1.377 296.797 1.532
202303 1.959 301.836 2.143
202306 1.994 305.109 2.158
202309 1.720 307.789 1.845
202312 1.234 306.746 1.328
202403 0.954 312.332 1.009
202406 1.809 314.175 1.901
202409 3.220 315.301 3.372
202412 2.773 315.605 2.901
202503 3.160 319.799 3.263
202506 2.254 322.561 2.307
202509 2.823 324.800 2.870
202512 3.765 324.054 3.837
202603 2.506 330.213 2.506

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €9.10 mean?
Bio-Rad Laboratories (FRA:BUWA) has a Cyclically Adjusted FCF per Share of €9.10 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Bio-Rad Laboratories and its competitors.
Is Bio-Rad Laboratories' Cyclically Adjusted FCF per Share too high?
Bio-Rad Laboratories' current Cyclically Adjusted FCF per Share is €9.10. Overall, Bio-Rad Laboratories has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bio-Rad Laboratories' Cyclically Adjusted FCF per Share compare to GKOS and BRKR?
Bio-Rad Laboratories' Cyclically Adjusted FCF per Share of €9.10 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted FCF per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Bio-Rad Laboratories and its competitors. Bio-Rad Laboratories's current Cyclically Adjusted FCF per Share is €9.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Rad Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Bio-Rad Laboratories (FRA:BUWA) is currently considered Fairly Valued. The stock's GF Value™ is €277.82, compared to a current price of €266.00 — trading 4.3% below its estimated fair value. The current Cyclically Adjusted FCF per Share is €9.10. Bio-Rad Laboratories' overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Bio-Rad Laboratories (FRA:BUWA), the current Cyclically Adjusted FCF per Share is €9.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bio-Rad Laboratories (FRA:BUWA) Overvalued in 2026?

Based on GuruFocus' analysis, Bio-Rad Laboratories stock appears to be undervalued. The current stock price of €266.00 is trading 4.3% below its estimated GF Value™ of €277.82. GuruFocus considers Bio-Rad Laboratories to be Fairly Valued.

Key valuation signals for FRA:BUWA:

  • Cyclically Adjusted FCF per Share: €9.10
  • GF Value™: €277.82 vs. price of €266.00 (4.3% below fair value)
  • GF Score™: 71/100 with 5 warning signs

No single metric tells the full story. See the FRA:BUWA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bio-Rad Laboratories Business Description

Address 1000 Alfred Nobel Drive, Hercules, CA, USA, 94547
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
71GF Score

Get the complete analysis for FRA:BUWA

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€266.00
Price
€277.82
GF Value